Vertex Pharmaceuticals upgraded to "neutral"

05/26/10 - Wedbush Morgan Securities

LONDON, May 26 (newratings.com) - Analysts at Wedbush Morgan upgrade Vertex Pharmaceuticals Incorporated (VRTX) from "underperform" to "neutral." The target price is set to $45.